Skip to main content
Clinical Trials/JPRN-UMIN000044902
JPRN-UMIN000044902
Recruiting
N/A

Effect of Dapagriflozin on renal dysfunction in patients with heart failure - Effect of Dapagriflozin on renal dysfunction in patients with heart failure

Mitsui Memorial Hospital0 sites100 target enrollmentJuly 19, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
chronic heart failure
Sponsor
Mitsui Memorial Hospital
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 19, 2021
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Contraindications in the attached text

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4]patients with type 2 diabetes
JPRN-UMIN000020185Diamond study group15
Active, Not Recruiting
Phase 1
The effect of treatment with Dapagliflozin on heart and kidney function after catheter based aortic valve replacement for aortic stenosisPatients with aortic stenosis undergoing trans catheter aortic valve replacement.MedDRA version: 20.0Level: LLTClassification code 10058186Term: Aortic valve stenosis and insufficiencySystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2021-004271-14-DKAarhus University Hospital, department of Cardiology104
Active, Not Recruiting
Phase 1
Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis interventioAortic stenosisTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
CTIS2024-514868-11-00Aarhus Universitetshospital106
Active, Not Recruiting
Phase 1
Effect of the dapagliflozin drug on the glomerular hyperfiltration in nondiabeticobese patients.This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glomerular hyperfiltration.Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
EUCTR2019-002262-12-ESHospital Universitari Germans Trias i Pujol60
Recruiting
Phase 4
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)
IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458